ArticleEJNMMI research2013
Radiofluorination using aluminum-fluoride (Al18F).
Article in EJNMMI research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 115 citations in OpenAlex.
- Mechanistic insights for the preparation of improved metal-fluoride based radioimaging agents.Chemical science · 2026Article
- Comparative Study of NOTA-Derived Chelators: Synthesis, AlInternational journal of molecular sciences · 2026Article
- Automated cGMP Radiosynthesis of [Molecular imaging and biology · 2026Article
- Easy and versatile preparation ofEJNMMI radiopharmacy and chemistry · 2026Article
- Aluminum-[EJNMMI radiopharmacy and chemistry · 2025Article
- Comparison of Al[Frontiers in oncology · 2025Article
- Article
- Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with AlBioconjugate chemistry · 2024Article
- Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.International journal of molecular sciences · 2024Review
- A versatile fluorinated azamacrocyclic chelator enablingChemical science · 2024Article
- PET Imaging of Peptide Probe Al[Molecular pharmaceutics · 2024Article
- Evaluation of [Pharmaceutics · 2023Article
- An optimized radiosynthesis of [Journal of labelled compounds & radiopharmaceuticals · 2023Article
- Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.International journal of molecular sciences · 2023Review
- [Frontiers in oncology · 2023Article
- Preparation, Optimisation, and In Vitro Evaluation of [Molecules (Basel, Switzerland) · 2022Article
- Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.EJNMMI research · 2022Review
- A kit-based aluminium-[Chemical communications (Cambridge, England) · 2021Article
- D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.Pharmaceutics · 2021Article
- Synthesis, preclinical evaluation, and a pilot clinical imaging study of [European journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted agents are increasingly used for treating cancer and other diseases, but patients may need to be carefully selected to maximize the potential for therapeutic benefit. One way to select patients is to bind an imaging radionuclide to a targeting agent of interest, so that its uptake in specific sites of disease can be visualized by positron-emission tomography (PET) or single-photon emission computed tomography.18F is the most commonly used radionuclide for PET imaging. Its half-life of approximately 2 h is suited for same-day imaging of many compounds that clear quickly from the body to allow visualization of uptake in the intended target. A significant impediment to its use, however, is the challenging coupling of 18F to a carbon atom of the targeting agent. Because fluorine binds to aluminum, we developed a procedure where the Al18F complex could be captured by a chelate, thereby greatly simplifying the way that imaging agents can be fluorinated for PET imaging. This article reviews our experience with this technology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.